Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

High-dose aldesleukin in renal cell carcinoma: long-term survival update.

Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S70-2.

PMID:
9457398
2.

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

Fisher RI, Rosenberg SA, Fyfe G.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S55-7.

PMID:
10685660
3.

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Atkins MB, Kunkel L, Sznol M, Rosenberg SA.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4.

PMID:
10685652
4.

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Review.

PMID:
9457399
5.

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC.

J Clin Oncol. 1995 Mar;13(3):688-96.

PMID:
7884429
6.

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7.

PMID:
9457402
7.

Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.

Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8.

PMID:
10685667
8.

[Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].

Sheng XN, Li JL, Guo J, Zhao XH, Zhu J, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2008 Feb;30(2):129-33. Chinese.

PMID:
18646697
9.
10.

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.

Besana C, Borri A, Bucci E, Citterio G, Di Lucca G, Fortis C, Matteucci P, Tognella S, Tresoldi M, Baiocchi C, et al.

Eur J Cancer. 1994;30A(9):1292-8.

PMID:
7999416
11.

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.

Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C, et al.

Eur J Cancer Clin Oncol. 1989;25 Suppl 3:S21-8.

PMID:
2697575
12.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M.

Cancer J Sci Am. 1997 May-Jun;3(3):157-62.

PMID:
9161781
14.

[Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].

Atzpodien J, Kirchner H, Poliwoda H.

Med Klin (Munich). 1996 Apr 12;91 Suppl 3:38-43. German.

PMID:
8692118
15.

Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.

Lissoni P, Bordin V, Vaghi M, Fumagalli L, Bordoni A, Mengo S, Bucovec R, Fumagalli E, Malugani F, Ardizzoia A, Giani L, Gardani GS, Tancini G.

Anticancer Res. 2002 Mar-Apr;22(2B):1061-4.

PMID:
12168901
16.

Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer.

Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP.

Eur Urol. 1999;35(3):204-9.

PMID:
10072621
17.

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.

Spanknebel K, Cheung KY, Stoutenburg J, Hurst-Wicker K, Hesdorffer C, Rn GD, Kaufman AH.

Ann Surg Oncol. 2005 May;12(5):381-90. Epub 2005 Apr 4.

PMID:
15915372
18.
19.

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.

Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, Franks CR, Selby P.

Cancer Biother. 1993 Winter;8(4):275-88.

PMID:
7804369
20.

Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.

Atzpodien J, Kirchner H, de Mulder P, Bodenstein H, Oliver T, Palmer PA, Franks CR, Poliwoda H.

Cancer Biother. 1993 Winter;8(4):289-300.

PMID:
7804370

Supplemental Content

Support Center